Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | TET3 | O43151 | 1/20 | 0.31 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.31 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.31 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.31 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.31 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25214265 | 0.85 | NPSR1 (0.41) | PNMTNPSR1AKR1C1CYP1A2CYP2C9 | |
| SCHEMBL2451987 | 0.76 | HSD11B1 (0.55) | HSD11B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2452042 | 0.75 | PNMT (0.59) | PNMTAKR1C1CYP2C9HDAC4HSD11B1 | |
| SCHEMBL5014698 | 0.74 | PNMT (0.46) | PNMTAKR1C1CYP2C9KMT2ADGAT1 | |
| SCHEMBL12302201 | 0.72 | PNMT (0.55) | PNMTAKR1C1CYP2C19HDAC4HSD11B1 | |
| SCHEMBL2453099 | 0.72 | PNMT (0.55) | PNMTAKR1C1CYP2C9HDAC4HSD11B1 | |
| SCHEMBL2452105 | 0.72 | NPSR1 (0.36) | NPSR1CYP1A2CYP2C9CYP2C19HDAC4 | |
| SCHEMBL2452508 | 0.69 | PNMT (0.52) | PNMTNPSR1AKR1C1HDAC4HSD11B1 | |
| SCHEMBL20743587 | 0.68 | PNMT (0.50) | PNMTAKR1C1HDAC4HSD11B1OPRM1 | |
| SCHEMBL1502311 | 0.68 | MEN1 (0.51) | PNMTAKR1C1HDAC4HSD11B1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| WO-2014113485-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8017603-B2 | Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-7749997-B2 | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors | ASTRAZENECA AB (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | PNMT 2027/4885NPSR1 259/4885AKR1C1 1875/4885 |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | PNMT 593/4885NPSR1 1405/4885AKR1C1 700/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | PNMT 1950/4885NPSR1 4476/4885AKR1C1 206/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | PNMT 2027/4885NPSR1 259/4885AKR1C1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.